Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris

Shots:

• The P-III PEMPHIX Study (NCT02383589) involves assessing of Rituxan (1000mg, IV) vs mycophenolate mofetil (MMF) in patients with moderate to severe active pemphigus vulgaris
• The P-III PEMPHIX study met its 1EPs & 2EPs and further demonstrated superior results to MMF in regards to sustained complete remission
• Rituxan (rituximab) is a mAb used to target cancer cells with CD20 marker and is a novel therapy approved by the US FDA in June 2018 for pemphigus vulgaris on basis of Ritux 3 clinical trial

Click here to read full press release/ article | Ref: Genentech | Image: Fortune